University of Utah Immunology, Inflammation, and Infectious Disease (3i) Initiative’s Post

New 3i Investigator Article Alert!! First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors https://lnkd.in/daUuU4Bs